Nuvectra Corp (NASDAQ:NVTR) has been given a consensus rating of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $24.00.
Several research firms have recently commented on NVTR. Raymond James began coverage on shares of Nuvectra in a report on Monday, November 19th. They issued an “outperform” rating and a $25.00 price target for the company. BidaskClub lowered shares of Nuvectra from a “buy” rating to a “hold” rating in a report on Saturday, November 10th. Zacks Investment Research lowered shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Thursday, November 8th. Finally, JMP Securities lifted their price target on shares of Nuvectra from $18.00 to $23.00 and gave the company a “market outperform” rating in a report on Wednesday, August 8th.
NASDAQ NVTR opened at $19.08 on Friday. Nuvectra has a one year low of $7.60 and a one year high of $25.17. The company has a quick ratio of 7.35, a current ratio of 7.63 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $305.69 million, a PE ratio of -4.52 and a beta of -0.34.
Nuvectra (NASDAQ:NVTR) last posted its quarterly earnings results on Monday, October 29th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.01). Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. The business had revenue of $14.22 million during the quarter, compared to analyst estimates of $12.38 million. Equities analysts forecast that Nuvectra will post -3.41 EPS for the current year.
In other Nuvectra news, President Joseph Paul Hanchin sold 1,600 shares of the business’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $18.18, for a total transaction of $29,088.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of NVTR. First Manhattan Co. acquired a new position in Nuvectra during the 2nd quarter valued at about $102,000. Metropolitan Life Insurance Co. NY acquired a new position in Nuvectra during the 2nd quarter valued at about $105,000. MetLife Investment Advisors LLC acquired a new position in Nuvectra during the 2nd quarter valued at about $148,000. GSA Capital Partners LLP acquired a new position in Nuvectra during the 3rd quarter valued at about $201,000. Finally, Financial Architects Inc boosted its stake in Nuvectra by 300.0% during the 2nd quarter. Financial Architects Inc now owns 10,000 shares of the company’s stock valued at $205,000 after purchasing an additional 7,500 shares during the period. 70.72% of the stock is owned by hedge funds and other institutional investors.
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.
Read More: Capital Gains
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.